What you should know about your Seroxat tablets This leaflet tells you about your tablets. Please read it before you start taking them. Do not throw this leaflet away as you may need to read it again when you stop taking your tablets.
SEROXAT (PAROXETINE) - Questions and Answers . What is Seroxat? Seroxat is the tradename for the medicine paroxetine, which has been used successfully to
Eight important things you need to know about Seroxat Please read all of the leaflet. It includes a lot of additional important information about this medicine.
GlaxoSmithKline (logo) Seroxat ® 10 mg, 20 mg and 30 mg tablets Paroxetine Patient Information Leaflet Seroxat ® Paroxetine Eight important things you need to know about Seroxat Please read all of the leaflet.
1 Seroxat User Group Doctor Pack Contents Halting SSRIs by David Healy MD FRCPsych.... 2 Withdrawal using liquid Seroxat (Seroxat Users Group)... 6 Dependence on Paroxetine (statement by David Healy MD FRCPsych Director of the North Wales department of Psychological medicine (University of Wales ...
8 THE BIG ISSUE IN SCOTLAND SEPTEMBER 12-18, 2002 . Seroxat on trial: DRUG . Giant set for legal battle More than 20 Scots are preparing to take GlaxoSmithKline to .
question 5: critical assessment of self-harm, suicidal behaviour and hostility data gsk - seroxat article 31 - question 5
MHRA Investigation into Glaxosmithkline/ Seroxat Summary This is a report produced by the Medicines and Healthcare products Regulatory Agency (MHRA) following the conclusion of an investigation concerning Glaxosmithkline (GSK) and the anti-depressant drug Seroxat.
3 Code of Practice ReviewAugust 2000 CASE AUTH/966/1/00 LUNDBECK v SMITHKLINE BEECHAM 'Dear Doctor' letter about Seroxat and citalopram Lundbeck complained about a letter sent to a doctor by SmithKline Beecham which compared that company's product Seroxat (paroxetine) with Lundbeck's product ...
THE MHRA INVESTIGATION INTO GSK'S REPORTING OF ADVERSE EVENTS IN SEROXAT PAEDIATRIC CLINICAL TRIALS By Tim Worden and Loretta Pugh Earlier this year, the Medicines and Health care products Regulatory Agency (the " MHRA ") published its report into GSK's alleged failure to report in a timely ...